Detalhe da pesquisa
1.
Healthcare costs and outcomes of managing ß-thalassemia major over 50 years in the United Kingdom.
Transfusion
; 56(5): 1038-45, 2016 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-27041389
2.
Systematic literature review of treatments for management of complications of ischemic central retinal vein occlusion.
BMC Ophthalmol
; 16: 104, 2016 Jul 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-27401800
3.
Using analogue data to substantiate long-term durability of gene therapies: a narrative review.
Regen Med
; 17(10): 767-782, 2022 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-35815392
4.
The use of innovative payment mechanisms for gene therapies in Europe and the USA.
Regen Med
; 16(4): 405-422, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33847163
5.
Clinical Adoption of Advanced Therapies: Challenges and Opportunities.
J Pharm Sci
; 110(5): 1877-1884, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-32918916
6.
Outcomes-based reimbursement for gene therapies in practice: the experience of recently launched CAR-T cell therapies in major European countries.
J Mark Access Health Policy
; 8(1): 1715536, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-32082514
7.
Upgrading the SACT dataset and EBMT registry to enable outcomes-based reimbursement in oncology in England: a gap analysis and top-level cost estimate.
J Mark Access Health Policy
; 7(1): 1635842, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-31303982
8.
Data collection infrastructure for patient outcomes in the UK - opportunities and challenges for cell and gene therapies launching.
J Mark Access Health Policy
; 7(1): 1573164, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-30774785
9.
The potential price and access implications of the cost-utility and budget impact methodologies applied by NICE in England and ICER in the US for a novel gene therapy in Parkinson's disease.
J Mark Access Health Policy
; 6(1): 1500419, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-30364868
10.
Establishing the cost of implementing a performance-based, managed entry agreement for a hypothetical CAR T-cell therapy.
J Mark Access Health Policy
; 6(1): 1511679, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-30151078
11.
Annuity payments can increase patient access to innovative cell and gene therapies under England's net budget impact test.
J Mark Access Health Policy
; 5(1): 1355203, 2017.
Artigo
em Inglês
| MEDLINE | ID: mdl-28839525
12.
Concise Review: The High Cost of High Tech Medicine: Planning Ahead for Market Access.
Stem Cells Transl Med
; 6(8): 1723-1729, 2017 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-28749065
13.
A price comparison of recently launched proprietary pharmaceuticals in the UK and the US.
J Mark Access Health Policy
; 42016.
Artigo
em Inglês
| MEDLINE | ID: mdl-27695606
14.
CRP2 transcript expression pattern in embryonic chick limb.
Mech Dev
; 116(1-2): 151-5, 2002 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-12128214
15.
Reimbursement of licensed cell and gene therapies across the major European healthcare markets.
J Mark Access Health Policy
; 32015.
Artigo
em Inglês
| MEDLINE | ID: mdl-27123175
16.
Market access pathways for cell therapies in France.
J Mark Access Health Policy
; 32015.
Artigo
em Inglês
| MEDLINE | ID: mdl-27123176
17.
Cell-based therapy technology classifications and translational challenges.
Philos Trans R Soc Lond B Biol Sci
; 370(1680): 20150017, 2015 Oct 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-26416686
18.
Bringing regenerative medicines to the clinic: the future for regulation and reimbursement.
Regen Med
; 10(7): 897-911, 2015.
Artigo
em Inglês
| MEDLINE | ID: mdl-26565607